Peer-influenced content. Sources you trust. No registration required. This is HCN.
Conexiant
The FDA approved a supplemental NDA adding randomized withdrawal trial data to the lumateperone label, supporting its role in long-term maintenance and relapse prevention in adults with schizophrenia.
Psychiatry May 13th 2026
Medical Professionals Reference (MPR)
Although most of these patients had no response to multiple seizure medications, the 9 who were treated with vitamin B6 supplementation had resolution of their seizures.
Neurology April 2nd 2026
“We are delivering on our promise to make sure women have accurate, scientifically grounded information about the potentially life-changing benefits of HRT.” — FDA Commissioner Marty Makary, MD, MPH
Obstetrics & Gynecology February 24th 2026
Specialty Pharmacy Continuum
As pharmacists, it’s crucial to note that, although these changes in FDA guidelines may not directly impact your practice, they signify a shift in how biosimilars will be identified moving forward. This could potentially influence how you advise patients about these products.
Clinical Pharmacology October 30th 2023
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS